SCHEMBL2480280

SCHEMBL2480280

O=C(O)c1cccc(-c2nn3c(c2-c2ccncc2)SCC3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.40
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
FABP5 Q01469 1/20 0.39
CSNK2A2 P19784 3/20 0.39
CSNK2B P67870 3/20 0.39
FOLH1 Q04609 1/20 0.38
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38
MAPK14 Q16539 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 1/20 0.37
MAP2K4 P45985 1/20 0.37
MAPKAPK3 Q16644 1/20 0.37
MAPK6 Q16659 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
GRM5 P41594 1/20 0.36
CD74 P04233 1/20 0.36
MIF P14174 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2482468 0.99 KMO (0.40) KMOFABP3FABP4FABP5CSNK2A2
SCHEMBL3465911 0.84 FYN (0.45) CSNK2A2CSNK2BCSNK1DCSNK1EMAPK14
SCHEMBL2479421 0.84 FYN (0.41) MAPK14FYN
SCHEMBL2474288 0.82 MAPK1 (0.44) KDM4EMAPK1NPC1RAB9A
SCHEMBL2478554 0.81 CYP17A1 (0.37) CSNK2A2CSNK2BCSNK1DCSNK1EMAPK14
SCHEMBL2479807 0.80 TP53 (0.42) NPC1RAB9A
SCHEMBL2477482 0.79 BCHE (0.45) MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL2481021 0.79 ROCK2 (0.48)
SCHEMBL2477335 0.79 BRAF (0.47) MAPK14NPC1RAB9A
SCHEMBL2481187 0.79 GRM5 (0.39) CSNK1DCSNK1EMAPK14GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 KMO 902/4885FABP3 1916/4885FABP4 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.